rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cronos Group Inc. - Common Share

CRON · Nasdaq

Health CarePharmaceuticalsLeadingCannabis

CRON stood above a rising 150-day average in 45 of the last 52 weekly readings, including each of the last 24 weeks. It is 15.0% above that average now. Pharmaceuticals: 37% of its 74 stocks in an uptrend (−1 points in four weeks); Health Care: 27% (−6 points in four weeks).

Statistics

Last close, 23 Oct 2026
3.35 −2.90%
52-week range
—
Volume
0.82M
Average volume (50 days)
—
Relative volume
—
Rotation
Leading
Weeks in an uptrend
24 in a row
Industry in uptrend
37% -1 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
2
Institutions holding
187 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 45 of 52 weeks.

24 Apr – 23 Oct
25%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Price and volume

$3.11$3.29$3.4711 Sep23 Sep5 Oct14 Oct23 Oct
close

Daily bars to 23 Oct 2026: 30 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 2, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
John A. Yarmuth House: U.S. House ClerkKY03bought$1k–$15k12 Feb 2021filed 19 Feb 2021
John A. Yarmuth House: U.S. House ClerkKY03bought$1k–$15k5 Nov 2020filed 15 Nov 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders187+5 on the quarter
New · exited27 · 22
Reported value$132.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
D. E. Shaw & Co., Inc.added · filed 14 Aug 20268,840,503$24.6M+1,222,276+16.0%
Chescapmanager LLCunchanged · filed 14 Aug 20267,942,737$22.1M00.0%
Tidal Investments LLCreduced · filed 13 Aug 20263,767,849$10.5M-259,043−6.4%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20263,048,254$8.5M+369,203+13.8%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPnew · filed 13 Aug 20261,992,855$5.5M+1,992,855
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20261,742,149$4.8M-267,400−13.3%
MACKENZIE FINANCIAL CORPnew · filed 13 Aug 20261,597,039$6.3M+1,597,039
CIBC WORLD MARKET INC.added · filed 13 Aug 20261,383,299$3.8M+36,479+2.7%
MMCAP International Inc. SPCunchanged · filed 14 Aug 2026999,490$2.8M00.0%
Quinn Opportunity Partners LLCunchanged · filed 14 Aug 2026969,033$2.7M00.0%
31 Mar 2023 – 30 Jun 2026
135161186Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Christopher Martens Company insiderGeneral Manager · last 16 Oct 20260 · 0
James Daniel Rudyk Company insiderDirector · last 6 Aug 20260 · 0
Jason Marc Adler Company insiderDirector · last 6 Aug 202625 · 7
Murray R. Garnick Company insiderDirector · last 6 Aug 20260 · 0
Adam Wagner Company insiderSee remarks · last 12 May 20260 · 0
Jared Matthew Kenost Company insiderOfficer · last 12 May 20260 · 0
Shannon Buggy Company insiderOfficer · last 12 May 20260 · 0
Terrence Gregory Joseph Doucet Company insiderOfficer · last 12 May 20260 · 0
Arye Weigensberg Company insiderOfficer · last 10 May 20260 · 0
Anna Shlimak Company insiderOfficer · last 19 Mar 20260 · 0
Jeffrey David Jacobson Company insiderChief Growth Officer · last 15 Mar 20260 · 1
Michael Ryan Gorenstein Company insiderSee remarks below · last 15 Mar 20260 · 7

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202542.8%
Operating profit marginFY 2025 · to 31 Dec 2025-11.9%
Free cash flow marginFY 2025 · to 31 Dec 20250.1%
Return on capital employedFY 2025 · to 31 Dec 2025-1.5%
Research spendFY 2025 · to 31 Dec 20253.0%
Share count trendFY 2025 · to 23 Feb 2026-0.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$791.8M
Free cash flowFY 2025 · to 31 Dec 2025$149K

Analyst forecasts

No analyst forecasts yet.